Rate Video

EBMT 2019 | CD19 CAR T-cell therapy for lymphoma

Michael Schmitt

EBMT 2019

Lymphoma Non-Hodgkin Lymphoma CAR-T

Michael Schmitt, MHBA, of University Hospital Heidelberg, Germany discusses CD19 CAR T-cell therapy against acute- and non-Hodgkin lymphoma. Being the 4th trial of its kind worldwide, Prof. Schmitt examines the need for new technology therapies to prevent patient relapse. This interview took place at the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting 2019, held in Frankfurt, Germany.

Pros and cons of autologous and allogeneic CAR-Ts

Michael Schmitt • 7 Feb 2022

Side effects of CAR T-cell therapy

Michael Schmitt

Exciting developments in the CAR space: novel target antigens, CAR-NKs & switchable CAR-Ts

Michael Schmitt • 7 Feb 2022

Preparing for the commercialization of CAR-T products

Michael Schmitt • 7 Feb 2022

Related Videos

Key challenges of using the intestinal microbiome as a biomarker

CAR T-cell therapy: the importance of LTFU

Axicabtagene ciloleucel in the real-world: safety and efficacy

Integration of CAR T-cell therapy: working with industry